A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies

Trial Profile

A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2011

At a glance

  • Drugs Gallium maltolate (Primary)
  • Indications Bladder cancer; Lymphoma; Multiple myeloma; Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Titan Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top